{"id":409224,"date":"2021-01-06T07:03:20","date_gmt":"2021-01-06T12:03:20","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=409224"},"modified":"2021-01-06T07:03:20","modified_gmt":"2021-01-06T12:03:20","slug":"olix-pharmaceuticals-to-present-at-2021-icr-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/olix-pharmaceuticals-to-present-at-2021-icr-conference\/","title":{"rendered":"OliX Pharmaceuticals to Present at 2021 ICR Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SUWON, Republic of Korea, Jan.  06, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rLPLoHrCfUQt5PfHwaF-RAwGMHjoEj-IKM5eWeRRxbLsGglecT_FmqF4NB8qzFI49HDU7SaPwDQLXV_Lp6kcuRM5Je-PjcM0i3VE3HbscAk=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">OliX Pharmaceuticals, Inc<\/a>. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company\u2019s management will present at the 2021 ICR Conference, being held virtually January 11-14, 2021.<\/p>\n<p align=\"justify\">Dong Ki Lee, Ph.D., Founder and Chief Executive Officer, will discuss OliX\u2019s pipeline, including its GalNAc-asiRNA program, liver-related program, OLX101A for hypertrophic scars, OLX301A for age-related macular degeneration and OLX301D for subretinal fibrosis.<\/p>\n<p align=\"justify\">Details for the upcoming virtual investor conference are below:<\/p>\n<p align=\"justify\">\n        <strong>2021 ICR Conference<\/strong>\n      <\/p>\n<p>Date: Thursday, January 14, 2021 <br \/>Presentation Track: Track 5 \u2013 Therapeutics (Public)<br \/>Presentation Time: 10:45 AM EST <br \/>Event Link:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nLA1jkPVL6EF_aCJ6CYdJibiQ_3-YAEhkwGLApUOAhf-7Aq1ge-2U5wRdp6Fs1maAduvqd1x9Po7XHZsg-waTXWvvmMEYXcHZS3KtJAhoiU=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/icrconference.com\/<\/a><\/p>\n<p>\n        <strong>Asymmetric small interfering RNA<\/strong>\n      <\/p>\n<p>Asymmetric small interfering RNA (asiRNA) is the next generation of RNAi therapeutics that offers efficient gene regulation. In comparison to existing siRNA therapeutics, OliX Pharmaceuticals\u2019 asiRNA shows comparable gene silencing and significantly reduces siRNA-mediated side effects such as off-target gene silencing and immune stimulation.<\/p>\n<p>\n        <strong>About OliX Pharmaceuticals<\/strong>\n      <\/p>\n<p>OliX Pharmaceuticals is a clinical stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating expression of disease-causing genes, based on its own proprietary RNAi technology. The Company\u2019s core RNAi platform, asymmetric siRNA (asiRNA), is a unique gene silencing technology based on RNA interference (RNAi), which is considered as the most efficient gene silencing technology. Based on asiRNA technology, OliX has developed cell penetrating asiRNA (cp-asiRNA), a therapeutic RNAi platform to effectively target locally administrable diseases, such as hypertrophic scar, dry and wet age-related macular degeneration (AMD), subretinal fibrosis, idiopathic pulmonary fibrosis (IPF), and neuropathic pain. OliX has also developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety of liver diseases.<\/p>\n<p>To learn more about the company, visit\u00a0<strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nLA1jkPVL6EF_aCJ6CYdJuNmlix5Bv7Hj6gB7Z90TtHx4aFA8WVZDxZuMlU8QDXR4CVXN2cCxI0tRVQdCiW9vUz4Il79R8cPxcaE8j2c3rpGr1ywMs5Evyw16QLefRy0\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/www.olixpharma.com\/eng\/<\/a><\/strong><br \/>To learn more about RNAi technology, visit\u00a0<strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nLA1jkPVL6EF_aCJ6CYdJuNmlix5Bv7Hj6gB7Z90TtGISpKOkc3CfDyDLcQSa94bzmzCR4xtMXK2PsCMrvVdpvCgZuGJ7htmPmc8dhbXBWMHFlhc0RXt34EVP0IpCPJk4YQICcgzc_tcHOS7rddlUA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/www.olixpharma.com\/eng\/rnd\/rnd01.php<\/a><\/strong><\/p>\n<p>\n        <strong>Media Contact:<\/strong>\n      <\/p>\n<p>Jon Yu<br \/>Westwicke\/ICR PR<br \/>Phone: +1.475.395.5375<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GCKdBxLgbdqvGwATUbjsNPvX3DkrOhyUNPEmROtI-rM2mn0bhSCH8FHI6OmW9eik6SPfzrpM3RqJtwib64C6on5tEqyRhe8ND9WDdpbapoc=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">jon.yu@westwicke.com<\/a>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTI2NiMzOTA2NDY4IzUwMDA3MTAxMw==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/9d2d9d91-5abb-4b64-9c96-ac7a7bf8579f\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SUWON, Republic of Korea, Jan. 06, 2021 (GLOBE NEWSWIRE) &#8212; OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company\u2019s management will present at the 2021 ICR Conference, being held virtually January 11-14, 2021. Dong Ki Lee, Ph.D., Founder and Chief Executive Officer, will discuss OliX\u2019s pipeline, including its GalNAc-asiRNA program, liver-related program, OLX101A for hypertrophic scars, OLX301A for age-related macular degeneration and OLX301D for subretinal fibrosis. Details for the upcoming virtual investor conference are below: 2021 ICR Conference Date: Thursday, January 14, 2021 Presentation Track: Track 5 \u2013 Therapeutics (Public)Presentation Time: 10:45 AM EST Event Link:\u00a0https:\/\/icrconference.com\/ Asymmetric small interfering RNA Asymmetric small interfering RNA (asiRNA) is the next generation of RNAi therapeutics that &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/olix-pharmaceuticals-to-present-at-2021-icr-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;OliX Pharmaceuticals to Present at 2021 ICR Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-409224","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>OliX Pharmaceuticals to Present at 2021 ICR Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/olix-pharmaceuticals-to-present-at-2021-icr-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OliX Pharmaceuticals to Present at 2021 ICR Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SUWON, Republic of Korea, Jan. 06, 2021 (GLOBE NEWSWIRE) &#8212; OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company\u2019s management will present at the 2021 ICR Conference, being held virtually January 11-14, 2021. Dong Ki Lee, Ph.D., Founder and Chief Executive Officer, will discuss OliX\u2019s pipeline, including its GalNAc-asiRNA program, liver-related program, OLX101A for hypertrophic scars, OLX301A for age-related macular degeneration and OLX301D for subretinal fibrosis. Details for the upcoming virtual investor conference are below: 2021 ICR Conference Date: Thursday, January 14, 2021 Presentation Track: Track 5 \u2013 Therapeutics (Public)Presentation Time: 10:45 AM EST Event Link:\u00a0https:\/\/icrconference.com\/ Asymmetric small interfering RNA Asymmetric small interfering RNA (asiRNA) is the next generation of RNAi therapeutics that &hellip; Continue reading &quot;OliX Pharmaceuticals to Present at 2021 ICR Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/olix-pharmaceuticals-to-present-at-2021-icr-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-06T12:03:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTI2NiMzOTA2NDY4IzUwMDA3MTAxMw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olix-pharmaceuticals-to-present-at-2021-icr-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olix-pharmaceuticals-to-present-at-2021-icr-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"OliX Pharmaceuticals to Present at 2021 ICR Conference\",\"datePublished\":\"2021-01-06T12:03:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olix-pharmaceuticals-to-present-at-2021-icr-conference\\\/\"},\"wordCount\":312,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olix-pharmaceuticals-to-present-at-2021-icr-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTI2NiMzOTA2NDY4IzUwMDA3MTAxMw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olix-pharmaceuticals-to-present-at-2021-icr-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olix-pharmaceuticals-to-present-at-2021-icr-conference\\\/\",\"name\":\"OliX Pharmaceuticals to Present at 2021 ICR Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olix-pharmaceuticals-to-present-at-2021-icr-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olix-pharmaceuticals-to-present-at-2021-icr-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTI2NiMzOTA2NDY4IzUwMDA3MTAxMw==\",\"datePublished\":\"2021-01-06T12:03:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olix-pharmaceuticals-to-present-at-2021-icr-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olix-pharmaceuticals-to-present-at-2021-icr-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olix-pharmaceuticals-to-present-at-2021-icr-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTI2NiMzOTA2NDY4IzUwMDA3MTAxMw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTI2NiMzOTA2NDY4IzUwMDA3MTAxMw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olix-pharmaceuticals-to-present-at-2021-icr-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OliX Pharmaceuticals to Present at 2021 ICR Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"OliX Pharmaceuticals to Present at 2021 ICR Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/olix-pharmaceuticals-to-present-at-2021-icr-conference\/","og_locale":"en_US","og_type":"article","og_title":"OliX Pharmaceuticals to Present at 2021 ICR Conference - Market Newsdesk","og_description":"SUWON, Republic of Korea, Jan. 06, 2021 (GLOBE NEWSWIRE) &#8212; OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company\u2019s management will present at the 2021 ICR Conference, being held virtually January 11-14, 2021. Dong Ki Lee, Ph.D., Founder and Chief Executive Officer, will discuss OliX\u2019s pipeline, including its GalNAc-asiRNA program, liver-related program, OLX101A for hypertrophic scars, OLX301A for age-related macular degeneration and OLX301D for subretinal fibrosis. Details for the upcoming virtual investor conference are below: 2021 ICR Conference Date: Thursday, January 14, 2021 Presentation Track: Track 5 \u2013 Therapeutics (Public)Presentation Time: 10:45 AM EST Event Link:\u00a0https:\/\/icrconference.com\/ Asymmetric small interfering RNA Asymmetric small interfering RNA (asiRNA) is the next generation of RNAi therapeutics that &hellip; Continue reading \"OliX Pharmaceuticals to Present at 2021 ICR Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/olix-pharmaceuticals-to-present-at-2021-icr-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-06T12:03:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTI2NiMzOTA2NDY4IzUwMDA3MTAxMw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olix-pharmaceuticals-to-present-at-2021-icr-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olix-pharmaceuticals-to-present-at-2021-icr-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"OliX Pharmaceuticals to Present at 2021 ICR Conference","datePublished":"2021-01-06T12:03:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olix-pharmaceuticals-to-present-at-2021-icr-conference\/"},"wordCount":312,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olix-pharmaceuticals-to-present-at-2021-icr-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTI2NiMzOTA2NDY4IzUwMDA3MTAxMw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olix-pharmaceuticals-to-present-at-2021-icr-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/olix-pharmaceuticals-to-present-at-2021-icr-conference\/","name":"OliX Pharmaceuticals to Present at 2021 ICR Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olix-pharmaceuticals-to-present-at-2021-icr-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olix-pharmaceuticals-to-present-at-2021-icr-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTI2NiMzOTA2NDY4IzUwMDA3MTAxMw==","datePublished":"2021-01-06T12:03:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olix-pharmaceuticals-to-present-at-2021-icr-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/olix-pharmaceuticals-to-present-at-2021-icr-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olix-pharmaceuticals-to-present-at-2021-icr-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTI2NiMzOTA2NDY4IzUwMDA3MTAxMw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTI2NiMzOTA2NDY4IzUwMDA3MTAxMw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olix-pharmaceuticals-to-present-at-2021-icr-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"OliX Pharmaceuticals to Present at 2021 ICR Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/409224","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=409224"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/409224\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=409224"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=409224"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=409224"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}